Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
申请人:Gunic Esmir
公开号:US20060217390A1
公开(公告)日:2006-09-28
This invention concerns certain 5-(substituted amino) isothiazoles, compounds of Formula I, and salts thereof,
where Q is CN, NHCONR
a
R
b
, or CONR
a
R
b
, where R
a
and R
b
are defined herein; and R
1
is cyclohexyl, adamantan-1-yl, indan-1-yl, phenyl, benzyl, pyridyl, pyridylmethyl, or pyrimidyl, where all aromatic R
1
groups are optionally substituted, provided that when R
1
is phenyl, then R
1
bears at least one non-alkyl substituent, and further provided that R
1
is not 4-chloro-3-trichloromethyl-phenyl;
The invention also concerns the tautomeric 5-(substituted amino)-isothiazol-3(2H)-ones, and the use of such compounds to treat Hepatitis C infection. It also concerns thiocarbamoyl acetamides, which are synthetic precursors to the isothiazoles.
这项发明涉及某些5-(取代氨基)异噻唑,化合物的结构式为I,以及其盐,其中Q为CN,NHCONRaRb或CONRaRb,其中Ra和Rb在此处定义;R1为环己基,金刚烷-1-基,茚-1-基,苯基,苄基,吡啶基,吡啶甲基或嘧啶基,其中所有芳香族R1基团均可选择性地取代,但当R1为苯基时,R1至少带有一个非烷基取代基,并且R1不是4-氯-3-三氯甲基苯基;该发明还涉及互变异构体5-(取代氨基)-异噻唑-3(2H)-酮,以及利用这些化合物治疗丙型肝炎感染。还涉及硫代氨基甲酰乙酰胺,它们是异噻唑的合成前体。